These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1617966)

  • 1. Serum and endometrial sodium and potassium levels with inert and copper-containing IUCDs and relation to serum steroid levels.
    Fahmy K; Ghoneim M; Eisa I; el-Gazar A; Afifi A
    Contraception; 1992 Jun; 45(6):573-81. PubMed ID: 1617966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of serum steroid hormones in intrauterine contraceptive device users.
    Fahmy K; el-Gazar A; Eisa I; Ghonaim M; Saad S; Afifi A
    Gynecol Endocrinol; 1991 Mar; 5(1):1-5. PubMed ID: 1897380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum and endometrial copper, zinc, iron and cobalt with inert and copper-containing IUCDs.
    Fahmy K; Ghoneim M; Eisa I; el-Gazar A; Afifi A
    Contraception; 1993 May; 47(5):483-90. PubMed ID: 8513675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal profile in IUD users.
    Souka AR; Rahman H; Osman M; Mohei Y; Rizk M
    Contracept Deliv Syst; 1981 Oct; 2(4):303-10. PubMed ID: 12336991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The menstrual cycle in women using an intrauterine device.
    Faundes A; Segal SJ; Adejuwon CA; Brache V; Leon P; Alvarez-Sanchez F
    Fertil Steril; 1980 Nov; 34(5):427-30. PubMed ID: 7439408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaginal pH effects caused by OCs and various copper and inert IUDs.
    Kandil O; Hassanein MK; El-tagi A; El-shirbini MT
    Contracept Deliv Syst; 1983 Jul; 4(3):187-93. PubMed ID: 12265361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical study comparing the performance of three IUCDs (Multiload Copper 250, Copper T 200, and Lippes Loop C).
    Fakhr MM; Fakhr DM; Hassan AA; Nasser NM
    Popul Sci; 1988; 8():39-53. PubMed ID: 12316112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copper levels in women using intrauterine devices or oral contraceptives.
    Hefnawi F; Kandil O; Askalani H; Zaki K; Nasr F; Mousa M
    Fertil Steril; 1974 Jul; 25(7):556-61. PubMed ID: 4841618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chlamydial serologic characteristics among intrauterine contraceptive device users: does copper inhibit chlamydial infection in the female genital tract?
    Mehanna MT; Rizk MA; Ramadan M; Schachter J
    Am J Obstet Gynecol; 1994 Sep; 171(3):691-3. PubMed ID: 8092216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
    Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The response of endometrial blood vessels to intrauterine contraceptive devices: an electron microscopic study.
    Sheppard BL; Bonnar J
    Br J Obstet Gynaecol; 1980 Feb; 87(2):143-54. PubMed ID: 7362802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of progesterone receptor mRNA in the endometrium during the normal menstrual cycle and in Norplant users.
    Lau TM; Witjaksono J; Affandi B; Rogers PA
    Hum Reprod; 1996 Dec; 11(12):2629-34. PubMed ID: 9021364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential.
    Greene KE; Kettel LM; Yen SS
    Fertil Steril; 1992 Aug; 58(2):338-43. PubMed ID: 1633899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum ovarian steroids, prolactin and prostaglandin metabolites in women using the inert intrauterine device.
    Shalev E; Harpaz-Kerpel S; Engelhard Y; Weiner E; Eran A; Zuckerman H
    Int J Gynaecol Obstet; 1987 Apr; 25(2):139-44. PubMed ID: 2884139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
    Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
    J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
    Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
    Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship of changes in serum estradiol and progesterone during the menstrual cycle to the thyrotropin and prolactin responses to thyrotropin-releasing hormone.
    Sawin CT; Hershman JM; Boyd AE; Longcope C; Bacharach P
    J Clin Endocrinol Metab; 1978 Dec; 47(6):1296-302. PubMed ID: 122427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do plain plastic and copper bearing intrauterine contraceptive devices have a central mechanism of action?
    Goldstuck ND
    Med Hypotheses; 1987 Jun; 23(2):125-30. PubMed ID: 2956487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of oral contraceptives on plasma neutral amino acids and cholesterol during a menstrual cycle.
    Moller SE; Moller BM; Olesen M; Fjalland B
    Eur J Clin Pharmacol; 1996; 50(3):179-84. PubMed ID: 8737756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a progesterone-releasing intrauterine contraceptive device on endometrial blood vessels: a morphometric study.
    Shaw ST; Macaulay LK; Aznar R; González-Angulo A; Roy S
    Am J Obstet Gynecol; 1981 Dec; 141(7):821-7. PubMed ID: 7315908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.